Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Nutr Neurosci ; 18(3): 110-7, 2015 Apr.
Article in English | MEDLINE | ID: mdl-24621067

ABSTRACT

OBJECTIVES: This study examined heat shock protein (HSP) 70 expression and rhythms of drinking behavior and locomotor activity in obesity, in order to clarify the involvement of HSPs in obesity-induced disturbance of circadian rhythms. METHODS: C57BL/6J ob/ob mice were used as a murine model of severe obesity. Drinking behavior and locomotor activity of male C57BL/6J (control) mice and ob/ob mice were recorded with the behavioral analyzing system. HSP70 concentration in the homogenized supernatant of each tissue, including the brain, liver, and kidney, was measured by an enzyme-linked immunosorbent assay. RESULTS: We observed an attenuated locomotor activity rhythm in the ob/ob mice compared with the control mice at 13 weeks of age and especially at 27 weeks of age. The drinking rhythm was little affected by obesity. HSP70 protein expression was reduced in the brain and kidney of the ob/ob mice compared with the control mice. However, HSP70 expression in the liver was not altered. DISCUSSION: This study suggests that the obesity-induced reduction of HSP70 expression in the brain and kidney can be directly or indirectly associated with disturbance of rhythms of the master clock and peripheral clocks. The study provides a link between circadian rhythm and HSP expression in obesity; the disturbance of these factors may lead to the progression of metabolic disorders.


Subject(s)
Circadian Rhythm/physiology , Drinking Behavior , Heat-Shock Proteins/metabolism , Motor Activity , Obesity/metabolism , Obesity/psychology , Animals , Behavior, Animal , Brain/metabolism , Disease Models, Animal , Kidney/metabolism , Liver/metabolism , Locomotion , Male , Mice , Mice, Inbred C57BL , Mice, Obese
2.
Radiol Phys Technol ; 7(2): 352-7, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24906451

ABSTRACT

A separate pulmonary vein (PV) is difficult to depict with the commonly used bright-blood magnetic resonance angiography method. Until now, no study has described the depiction of peripheral PVs without the artery. Our purpose in this study was to develop an arterial spin labeling (ASL)-based magnetic resonance angiography sequence to depict the pulmonary artery (PA) and vein separately. We developed such a sequence by using two inversion recovery pulses. The first pulse was non-selective, and the second pulse was selective and was applied to the aorta and heart. All studies were conducted on a 1.5-T clinical magnetic resonance system with six different inversion times for seven healthy volunteers. For evaluation, we categorized the inversion times by using visual scoring. Then, we used the magnitude image to evaluate the PA, and we used the real image to evaluate the PV. For the PA, an inversion time of 300 ms had the lowest score (1.43), and the score changed with increasing times; an inversion time of 1,100 ms had the highest score (3.85). For the PV, an inversion time of 300 ms had the highest score (2.68), and the score decreased with increasing times. The results indicated that the PA and vein could be depicted separately by the use of an ASL-based magnetic resonance angiography method. The optimal inversion times for the PV and artery were 300 and 1,100 ms, respectively.


Subject(s)
Magnetic Resonance Angiography/methods , Pulmonary Artery/diagnostic imaging , Pulmonary Veins/diagnostic imaging , Spin Labels , Adult , Humans , Radiography , Young Adult
3.
Life Sci ; 89(17-18): 662-70, 2011 Oct 24.
Article in English | MEDLINE | ID: mdl-21872612

ABSTRACT

AIMS: The objectives of this study were to elucidate the effects of a potent dipeptidyl peptidase (DPP)-IV inhibitor, TS-021, combined with/without metformin on glycemic control and pathological changes in pancreatic islets in high-fat diet and streptozotocin-induced (HFD-STZ) diabetic mice. MAIN METHODS: The anti-diabetic effects of TS-021 and/or metformin in HFD-STZ mice were examined in both acute and chronic treatment studies. In addition, we performed immunohistochemical analysis after repeated administration of TS-021 and/or metformin to HFD-STZ mice twice a day for 5 weeks. KEY FINDINGS: In the acute treatment study, TS-021 and/or metformin significantly improved glucose tolerance and glucagon-like peptide-1 (GLP-1) level, and TS-021 alone or in combination with metformin significantly increased the plasma insulin level after nutrient ingestion. In the chronic treatment study, TS-021 in combination with metformin significantly lowered the glycosylated hemoglobin level, plasma insulin level, and α-cell-to-ß-cell area ratio in pancreatic islets. In particular, the combined treatment synergistically increased the insulin-positive area in pancreatic islets from 32.3% in diabetic mice treated with the vehicle to 51.1% (TS-021 alone, 35.3%; metformin alone, 30.6%). SIGNIFICANCE: The present study demonstrated that the coadministration of TS-021 and metformin synergistically improved the islet morphology by increasing the circulating level of biologically active GLP-1, which is thought to result from two different mechanisms (namely, an increase in GLP-1 secretion and DPP-IV inhibition). These findings strongly support the rationale for combined treatment with DPP-IV inhibitors plus metformin in clinical practice by clearly demonstrating an anti-diabetic effect associated with the remarkable improvement in pancreatic ß-cell morphology.


Subject(s)
Benzenesulfonates/therapeutic use , Diabetes Mellitus, Type 2/drug therapy , Hyperglycemia/drug therapy , Hypoglycemic Agents/therapeutic use , Insulin-Secreting Cells/drug effects , Metformin/therapeutic use , Pyrrolidines/therapeutic use , Animals , Benzenesulfonates/pharmacology , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/metabolism , Diabetes Mellitus, Type 2/pathology , Dipeptidyl Peptidase 4/metabolism , Drug Synergism , Glucagon-Like Peptide 1/blood , Glycated Hemoglobin/analysis , Hyperglycemia/blood , Hyperglycemia/metabolism , Hyperglycemia/pathology , Hypoglycemic Agents/pharmacology , Insulin/blood , Insulin-Secreting Cells/metabolism , Insulin-Secreting Cells/pathology , Male , Metformin/pharmacology , Mice , Mice, Inbred C57BL , Pyrrolidines/pharmacology
4.
J Pharmacol Sci ; 97(1): 132-7, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15655287

ABSTRACT

The present study examined the contribution of 20-hydroxy-5,8,11,14-eicosatetraenoic acid (20-HETE) in cyclosporine A (CsA)-induced renal nephrotoxicity. Treatment of rats with CsA (50 mg/kg) for 9 days induced renal damage as indicated by marked increase in urine flow (from 9.0 +/- 0.3 ml/day to 46.6 +/- 7.1 ml/day) and a 3 - 5-fold rise in blood urea nitrogen (BUN) levels. The urinary excretion of 20-HETE increased from 164 +/- 5 ng/day (N = 5) to 2432 +/- 290 ng/day (N = 5, P<0.01) after 9 days of CsA treatment. The increase in the urinary excretion of 20-HETE in the CsA treated rats was highly correlated with the increase in BUN levels (r = 0.819, P<0.001) and urine volume (r = 0.832, P<0.001). Immunohistochemical examination of kidney revealed that expression of cytochrome P450 4A (CYP4A) protein was markedly enhanced in the proximal tubules of CsA-treated rats. These results indicate that CsA-induced nephrotoxicity in rats is associated with a marked elevation in the renal production of 20-HETE and that 20-HETE may contribute to the pathophysiological condition of CsA-induced nephrotoxicity.


Subject(s)
Cyclosporine/adverse effects , Hydroxyeicosatetraenoic Acids/urine , Kidney Diseases/chemically induced , Kidney Diseases/urine , Animals , Blood Urea Nitrogen , Creatinine/blood , Cyclosporine/metabolism , Cyclosporine/therapeutic use , Cytochrome P-450 CYP4A/chemistry , Cytochrome P-450 CYP4A/drug effects , Cytochrome P-450 CYP4A/genetics , Drug Administration Schedule , Gene Expression/drug effects , Gene Expression/genetics , Hydroxyeicosatetraenoic Acids/adverse effects , Injections, Intraperitoneal , Kidney Cortex/drug effects , Kidney Cortex/metabolism , Kidney Cortex/ultrastructure , Male , Rats , Rats, Sprague-Dawley , Time Factors , Urine/chemistry , Urine/physiology , Urodynamics/drug effects , Urodynamics/physiology
5.
Eur J Pharmacol ; 486(3): 297-306, 2004 Feb 23.
Article in English | MEDLINE | ID: mdl-14985052

ABSTRACT

This study examined the effects of a 20-hydroxyeicosatetraenoic acid (20-HETE) antagonist, 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid (WIT002) and two agonists, 4-amino-N-(20-hydroxy-eicosa-5(Z),14(Z)-dienoyl) benzenesulfonamide (ABSA) and 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid (WIT003), on the diameter of rat middle cerebral arteries in vitro and on cerebral blood flow in vivo. WIT003, ABSA and 20-HETE all had a similar effect to reduce the diameter of the middle cerebral artery by 26%. WIT003 and 20-HETE both increased intracellular Ca2+ concentration ([Ca2+]i) in vascular smooth muscle cells isolated from the middle cerebral artery. In contrast, WIT002 had no effect on the basal diameter of the middle cerebral artery but it attenuated the vasoconstrictor responses and the rise in [Ca2+]i in vascular smooth muscle cells following administration of 20-HETE and 5-hydroxytryptamine (5-HT). WIT003 partially restored the vasoconstrictor response to 5-HT in the middle cerebral artery after administration of an inhibitor of the endogenous synthesis of 20-HETE. Infusion of the 20-HETE agonists, WIT003 and ABSA, into cisterna magna of rats reduced baseline cerebral blood flow by 20%, whereas administration of the 20-HETE antagonist, WIT002, had no effect. Intracisternal injection of WIT002 attenuated the fall in cerebral blood flow following injection of blood into the cisterna magna, whereas administration of the 20-HETE agonist, ABSA, potentiated this response. These findings indicate that the 20-HETE agonists, WIT003 and ABSA, increase cerebral vascular tone both in vivo and in vitro and suggest blocking the vasoconstrictor actions of 20-HETE may be useful to prevent the acute fall in cerebral blood flow following subarachnoid hemorrhage.


Subject(s)
Cerebrovascular Circulation/drug effects , Hydroxyeicosatetraenoic Acids/agonists , Hydroxyeicosatetraenoic Acids/antagonists & inhibitors , Hydroxyeicosatetraenoic Acids/pharmacology , Muscle, Smooth, Vascular/drug effects , Vasoconstriction/drug effects , Animals , Calcium/metabolism , Drug Interactions , In Vitro Techniques , Male , Middle Cerebral Artery/drug effects , Middle Cerebral Artery/physiology , Muscle, Smooth, Vascular/physiology , Rats , Rats, Sprague-Dawley , Regional Blood Flow/drug effects , Subarachnoid Hemorrhage/physiopathology , Time Factors , Vasoconstriction/physiology
6.
Bioorg Med Chem ; 11(13): 2803-21, 2003 Jul 03.
Article in English | MEDLINE | ID: mdl-12788354

ABSTRACT

The effects of natural and synthetic eicosanoids on the diameter of rat interlobular arteries studied in vitro were compared to that of the potent, endogenous vasoconstrictor 20-HETE. Vasoconstrictor activity was optimum for chain lengths of 20-22 carbons with at least one olefin or epoxide between located between C(13)-C(15) and an oxygen substituent at C(20)-C(22). The presence of delta (Zou et al. Am. J. Physiol. 1996, 270, R228; Gebremedhin, D. et al. Am. J. Physiol. 1998, 507, 771)-, delta (Carroll et al. Am. J. Physiol. 1996, 271, R863; Vazquez et al. Life Sci. 1995, 56, 1455)-, or delta (Imig et al. Hypertension 2000, 35, 307; Lopez et al. Amer. J. Physiol. 2001, 281, F420)-olefins had no influence on the vasoconstrictor response whereas the introduction of a C(7)-thiomethylene enhanced potency. A sulfonamide or alcohol, but not a lactone, could replace the C(1)-carboxylate. These data were used to construct a putative binding domain map of the 20-HETE receptor consisting of: (i) a comparatively open, hydrophilic binding site accommodating the C(1)-functionality; (ii) a hydrophobic trough spanning the olefins; (iii) a shallow pocket containing a critical pi-pi binding site in the vicinity of the pi (Ito et al. Am. J. Physiol. 1998, 274, F395; Quigley, R.; Baum, M.; Reddy, K. M.; Griener, J. C.; Falck, J. R. Am. J. Physiol. 2000, 278, F949)-olefin; and (iv) an oxyphilic binding site proximate to the omega-terminus.


Subject(s)
Hydroxyeicosatetraenoic Acids/chemical synthesis , Hydroxyeicosatetraenoic Acids/pharmacology , Vasoconstriction/drug effects , Animals , Binding Sites , Kidney/blood supply , Magnetic Resonance Spectroscopy , Rats , Receptors, Eicosanoid/chemistry , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...